All In Biotech

Drug Trial Radar · NCT05940116

A Phase I Clinical Study of HS-20117 in Participants With Advanced Solid Tumors

A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HS-20117 in Participants With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Jul 12, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

322

Planned (sponsor's estimate)

Start

Jul 20, 2023

Primary completion

Jul 30, 2025

Study completion Jul 30, 2027

Sponsor

Lead sponsor
Hansoh BioMedical R&D CompanyIndustry
Sponsor type
Industry
First posted
Jul 11, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

HS-20117 is a fully-human EGFR-MET immunoglobulin G1(IgG1)-like bispecific antibody. The purpose of study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of HS-20117 as a monotherapy for participants with advanced solid tumors.

Conditions

  • Non-Small Cell Lung Cancer
  • Solid Tumor

Interventions

  • HS-20117Drug

    Phase Ia: patients will receive HS-20117 starting at 400 mg, and subsequent cohorts will test escalating doses, if tolerated, until a maximum tolerated dose (MTD) or maximum applicable dose (MAD) is defined. Phase Ib: patients will receive HS-20117 at MED or MAD

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. [Phase 1a] Maximum tolerated dose (MTD) of HS-20117Time frame: Cycle 1 (28 days)
  2. [Phase 1a] Maximum applicable dose (MAD) of HS-20117Time frame: Cycle 1 (28 days)
  3. [Phase 1b] Efficacy of HS-20117: Objective response rate (ORR)Time frame: From the date of first dose until the date of disease progression or withdrawal from study, approximately 2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Tianjin Medical University Cancer Institute and Hospital

    Tianjin, Tianjin Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.